Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors
June 28 2017 - 4:30PM
Business Wire
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS;
Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused
on developing immunotherapies based on gene-edited CAR T-cells
(UCART), today announced that it has appointed Rainer Boehm, M.D.
and Hervé Hoppenot to its Board of Directors.
“We are delighted to welcome Rainer Boehm and Hervé Hoppenot to
our Board. Rainer’s experience in drug commercialization will be
invaluable as we work to develop the next generation CAR T-cell
immunotherapies. Hervé brings deep expertise in oncology which will
be a major benefit to our team we continue to innovate to bring
UCART product candidates to the clinic,” said André Choulika, CEO
Cellectis. “With these two esteemed leaders, we are adding to the
expertise of our Board of Directors to help guide Cellectis into
our next phase.”
Rainer Boehm spent 29 years at Novartis, working locally,
regionally and globally in various Senior Management roles, after
building his career in Marketing & Sales and Medical Affairs.
He led all emerging markets regions as well as the United States
and Canada, either for Oncology or the Pharmaceuticals division.
His most recent assignments were Chief Commercial and Medical
Affairs Officer globally for Novartis Pharma, as well as ad interim
CEO and Division Head Pharma. Rainer launched and oversaw the
commercialization of many brands during his career, amongst them
Femara, Zometa and Glivec, as well as Cosentyx and Entresto. His
broad interests include leadership development, coaching and
mentoring, access to medicines and new business models including
solutions to leverage digital medicines and real world evidence.
Rainer has a medical degree from the University of Ulm in Germany,
and a Master of Business Administration from Schiller University in
France.
“I am honored to join the Board and look forward to providing
strategic advice on drug commercialization to strengthen Cellectis’
market leading position. Cellectis is a company with tremendous
potential,” said Rainer Boehm, Cellectis’ newest Board member. “I
see exciting opportunities for Cellectis to address unmet medical
needs and make a meaningful difference in people’s lives. What
Cellectis is accomplishing is transformative and we have the
potential to move the needle forward for healthcare in a positive
way.”
Hervé Hoppenot joined Incyte Corporation in 2014 as President
and Chief Executive Officer, and was appointed Chairman of the
Board of Directors in 2015. Incyte is one of the fastest growing
biopharmaceutical companies in the U.S. Incyte’s team of more than
1,000 scientists, clinicians, and other team members operating in
15 countries, strives to discover and develop first-in-class and
best-in-class medicines for cancer and other diseases. The Company
is advancing a diverse portfolio of large and small molecules
comprised of 18 development candidates against 14 different
molecular targets and in 2016 Incyte reported revenue of more than
$1 billion.
Prior to joining Incyte, Mr. Hoppenot was the President of
Novartis Oncology, which included $11 billion in global sales, the
largest oncology pipeline in the industry and 8000 employees in 50
countries. Prior to joining Novartis in 2003, Mr. Hoppenot started
his career in 1983 with Rhone Poulenc, later known as Aventis,
where he served in several senior roles of increasing
responsibility, including Vice President of Oncology and Head of
the US Oncology business unit. He and his family are dual citizens
of France and the United States, having moved to the U.S. in
1991.
"Despite many advances in oncology, there remains a need to
continue to advance the science to meet the needs of patients.
Through its work in developing CAR T immunotherapies, Cellectis has
an opportunity to make a significant contribution to the treatment
of cancer,” Mr. Hoppenot said. "I am excited to be joining the
Cellectis Board during this important time of growth."
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused
on developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 17 years of
expertise in gene editing – built on its flagship TALEN® technology
and pioneering electroporation system PulseAgile – Cellectis uses
the power of the immune system to target and eradicate cancer
cells. Using its life-science-focused, pioneering genome
engineering technologies, Cellectis’ goal is to create innovative
products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the
NYSE Alternext market (ticker: ALCLS). To find out more about us,
visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an
offer to buy or subscribe, for shares in Cellectis in any country.
This press release contains forward-looking statements that relate
to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements above.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170628006216/en/
CellectisMedia:Jennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2023 to Apr 2024